ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Relat
November 16, 2020Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the results of the ... -
Novartis to file Lucentis for rare sight condition in premature babies
September 27, 2018Novartis has revealed its intent to file anti-VEGF therapy Lucentis for retinopathy of prematurity (ROP), a rare disease...
Pharma Sources Insight January 2025
